Amgen Inc. (NASDAQ:AMGN) Shares Purchased by CapWealth Advisors LLC

CapWealth Advisors LLC grew its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,988 shares of the medical research company’s stock after purchasing an additional 350 shares during the period. CapWealth Advisors LLC’s holdings in Amgen were worth $8,637,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in AMGN. Vanguard Group Inc. increased its position in shares of Amgen by 0.3% during the third quarter. Vanguard Group Inc. now owns 49,035,981 shares of the medical research company’s stock worth $13,178,910,000 after acquiring an additional 165,636 shares during the period. Morgan Stanley increased its position in shares of Amgen by 12.9% during the fourth quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock worth $3,493,471,000 after acquiring an additional 1,523,665 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Amgen by 1.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 8,819,690 shares of the medical research company’s stock worth $2,132,778,000 after acquiring an additional 94,565 shares during the period. Moneta Group Investment Advisors LLC increased its position in shares of Amgen by 83,875.6% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock worth $1,980,571,000 after acquiring an additional 7,532,031 shares during the period. Finally, Northern Trust Corp increased its position in shares of Amgen by 3.8% during the third quarter. Northern Trust Corp now owns 6,977,625 shares of the medical research company’s stock worth $1,875,306,000 after acquiring an additional 255,463 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. StockNews.com lowered Amgen from a “buy” rating to a “hold” rating in a research report on Thursday, March 28th. Oppenheimer reissued an “outperform” rating and issued a $350.00 target price on shares of Amgen in a report on Thursday, February 1st. Daiwa Capital Markets raised Amgen from a “neutral” rating to a “buy” rating and increased their target price for the company from $264.00 to $320.00 in a report on Thursday, December 21st. The Goldman Sachs Group increased their target price on Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a report on Wednesday, February 7th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $329.00 price objective on shares of Amgen in a report on Wednesday, April 3rd. Ten equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, Amgen currently has an average rating of “Moderate Buy” and an average target price of $296.95.

Amgen Price Performance

Shares of AMGN stock traded up $0.03 during midday trading on Thursday, reaching $264.10. 534,393 shares of the company traded hands, compared to its average volume of 2,831,060. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The firm’s 50 day simple moving average is $277.99 and its two-hundred day simple moving average is $281.37. Amgen Inc. has a 1-year low of $211.71 and a 1-year high of $329.72. The firm has a market cap of $141.54 billion, a PE ratio of 21.14, a price-to-earnings-growth ratio of 2.47 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business had revenue of $8.20 billion during the quarter, compared to analysts’ expectations of $8.13 billion. During the same period last year, the company posted $4.09 EPS. The company’s revenue was up 19.8% on a year-over-year basis. On average, equities research analysts expect that Amgen Inc. will post 19.46 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. The ex-dividend date is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.41%. Amgen’s dividend payout ratio (DPR) is 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.